News

Semaglutide and Kidney Disease: The Full Picture

Creator: Priya Raman, Health Writer
Published: 2026-09-12

In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.

Priya Raman, Health Writer September 12, 2026 6 min read

A woman sits on a wooden stool at a kitchen counter, peeling an orange over a plain bowl

The short version

In FLOW, a 2024 trial of 3,533 adults with type 2 diabetes and kidney disease, serious kidney events happened to 331 people on semaglutide against 410 on placebo — a 24% lower risk over about three and a half years.
A pooled analysis of three trials published on August 7, 2026 covered 30,787 people, including a group with heart disease and obesity but no diabetes, and pointed the same way: 973 first kidney events on semaglutide against 1,134 on placebo.
One kidney risk runs through dehydration, but [a June 2026 systematic review](https://doi.org/10.3389/fmed.2026.1793349) also included biopsy-confirmed acute interstitial nephritis, focal segmental glomerulosclerosis and minimal change disease. The label warns about sudden kidney injury in people whose nausea, vomiting or diarrhea dried them out, and tells prescribers to check kidney function when that happens.
The FDA added a kidney use to the branded weekly injection on January 28, 2025. Promise dispenses semaglutide as a compounded medication, which is different from an FDA-approved product: that formulation is not FDA-approved and is prescribed for weight management.
eGFR — an estimate of filtering speed from a routine blood test — is the number a provider wants before starting and watches afterwards. The label calls for no dose change in reduced kidney function.

Semaglutide and kidney disease is a pairing that sounds like a warning. Mostly it is the opposite. In the largest trial run on the question, adults who had both type 2 diabetes and kidney disease and took semaglutide had about a quarter fewer serious kidney events than the people who got a placebo — a wide enough gap that the trial was stopped early.

There is a second, smaller story that keeps getting tangled up with the first one. Semaglutide can make people vomit. Vomiting dries you out. Dehydration is hard on kidneys. That risk is real and printed on the label, but published case reports also include biopsy-confirmed kidney injuries that cannot all be attributed to dehydration.

Both are true. Here is how they fit together.

What "kidney disease" actually means here

Your kidneys filter your blood. The usual way to measure how well is eGFR — an estimate of filtering speed, worked out from a routine blood test. A healthy adult tends to run around 90 or above. Numbers that stay under 60 are what doctors call chronic kidney disease.

The second number is albumin in your urine. Albumin is a protein that is supposed to stay in the blood, so finding it in urine means the filter is leaking. Plenty of people are leaking before their eGFR has moved at all.

"Chronic" is carrying weight there: months and years of slow decline, not one rough week. It is also usually silent — most people find out from a blood test rather than from feeling anything.

What the trials say about semaglutide and kidney disease

The trial everyone means is FLOW, published in the New England Journal of Medicine in 2024. It enrolled 3,533 adults who had type 2 diabetes and kidney disease, gave half of them a weekly 1 mg semaglutide injection and half a placebo, and followed them for a median of about three and a half years.

What was counted was a bundle of bad outcomes: kidney failure, a halving of filtering capacity, or death from kidney or heart causes. That happened to 331 people on semaglutide and 410 on placebo — a 24% lower risk. Filtering declined more slowly in the semaglutide group as well, deaths from any cause were 20% lower, and a planned interim look showed the gap clearly enough that the trial was stopped ahead of schedule.

Worth holding onto: that was the branded weekly injection, at a fixed dose, in people who already had both conditions — not a study of semaglutide as a kidney treatment for everybody.

The newest numbers, as of September 2026

As of September 6, 2026, the day this article was written, the most recent kidney evidence on semaglutide is a pooled analysis published in The Lancet Diabetes & Endocrinology on August 7, 2026. The researchers combined individual participant data from three trials — FLOW, plus SELECT and SOUL — for 30,787 people in all.

Who was in the other two is the interesting part. SELECT enrolled people with heart disease and obesity but no diabetes; SOUL used the daily tablet rather than a weekly shot. So the pooled group is far broader than the diabetes-plus-kidney-disease population FLOW studied.

Across all three, a first kidney event was recorded in 973 people on semaglutide and 1,134 on placebo, and a narrower count that left out heart deaths ran the same way. The authors write that the benefit may not be explained by blood-sugar or weight effects alone. Serious side effects were no more common on semaglutide than on placebo.

What the label actually says

On January 28, 2025, the FDA approved a new use for the branded weekly injection: reducing the risk of sustained eGFR decline, end-stage kidney disease and death from cardiovascular causes in adults with type 2 diabetes and chronic kidney disease. That is the FLOW result written into the prescribing information.

Two details get skipped. The kidney use sits on the injectable brand only — the oral semaglutide tablets carry blood-sugar and heart indications, not the kidney one. And none of it describes what a compounding pharmacy prepares.

Promise dispenses semaglutide as a compounded medication, which is different from an FDA-approved product: the formulation offered here — semaglutide with vitamin B12 — is not FDA-approved, and it is prescribed for weight management rather than as a treatment for kidney disease. A licensed provider can still decide a compounded formulation is appropriate; that decision sits between you and the doctor reading your file. If the brand-versus-compounded distinction is the part you want spelled out, what compounded semaglutide is walks through it.

The other story: dehydration

Now the risk. The Ozempic prescribing information, last revised in May 2026, carries a warning headed "Acute Kidney Injury Due to Volume Depletion." After the drug reached the market there were reports of sudden kidney injury, some serious enough to need dialysis. Most of those people had been nauseated, vomiting or had diarrhea badly enough to get dehydrated first.

The label tells prescribers to check kidney function in anyone reporting symptoms like that, especially in the first weeks and while a dose is going up.

How often? Rarely, as far as anyone can measure. A systematic review published in Frontiers in Medicine in June 2026 screened 1,039 publications and turned up 20 reported cases across 18 studies, worldwide, covering everything published through October 2025. Seventeen of the twenty improved or recovered. Case reports cannot give you a rate — they show the shape of a problem, not the odds of it.

The case reports did not all have one shape. Some followed nausea, vomiting or diarrhea, while others involved biopsy-confirmed kidney injuries without that pattern (systematic review). The nausea on its own is common and usually settles; semaglutide side effects covers what is typical and what is not. That is one route to kidney injury, not the only one.

eGFR is the number your provider watches

The label says no dose adjustment is needed for reduced kidney function, and semaglutide's behaviour in the body barely changes even in kidney failure. That is not the same as saying kidney function does not matter.

A provider reviewing an intake wants a recent eGFR for a plain reason: a baseline. Without one there is nothing to compare a later reading against. They will want the rest of the medicine cabinet too — water pills, anti-inflammatories like ibuprofen and some blood-pressure drugs put their own load on the same organ.

A licensed provider reviews every request and not everyone qualifies. A history of kidney trouble is one of the things that can change the answer, in either direction.

The ongoing part is simpler than it sounds: a day or two of not being able to keep fluids down is a reason to call the prescriber rather than wait it out.

Where tirzepatide sits

Tirzepatide has no trial like FLOW behind it. The nearest thing is a post-hoc analysis of SURPASS-4 published in The Lancet Diabetes & Endocrinology in 2022, in which people on tirzepatide lost filtering capacity more slowly and leaked less albumin than people on insulin glargine over a median of 85 weeks. Post-hoc means the question was asked after the trial had finished, which is real evidence but weaker than a trial built to answer it.

No tirzepatide product carries a kidney use on its label as of this writing; the Mounjaro label, revised August 2026, lists blood sugar and cardiovascular risk only. If you are weighing the two against each other, tirzepatide versus semaglutide compares them across the board.

What to bring to a first visit

If your kidneys are the reason you are asking, three things make the review worth something: your most recent kidney labs, the full list of what you take, and any history of a stomach bug that put you in a clinic. If you are managing type 2 diabetes too, semaglutide for type 2 diabetes covers the blood-sugar side.

Common questions

Is semaglutide safe if I have kidney disease?

That is the question FLOW was built to answer, in 3,533 adults who had both type 2 diabetes and chronic kidney disease. Serious kidney events were 24% less common on semaglutide than on placebo over about three and a half years, and serious adverse events were no more frequent. Whether it suits you still depends on your own numbers and medications, which is what a provider reviews before prescribing.

Can semaglutide damage your kidneys?

Many reported cases followed dehydration, but [a June 2026 systematic review](https://doi.org/10.3389/fmed.2026.1793349) also included biopsy-confirmed acute interstitial nephritis, focal segmental glomerulosclerosis and minimal change disease. The prescribing information describes reports of sudden kidney injury after the drug reached the market, mostly in people whose nausea, vomiting or diarrhea left them dried out, and a few needed dialysis. A published review found 20 such cases worldwide through October 2025. Not being able to keep fluids down is one warning sign.

Is compounded semaglutide FDA-approved for kidney disease?

No. FDA-approved semaglutide products exist — the branded weekly injection gained a kidney use on January 28, 2025 — but the compounded formulation offered here is not FDA-approved, and it is prescribed for weight management rather than for kidney disease. A licensed provider can still decide a compounded formulation is appropriate; that judgment sits with them and with you.

Does semaglutide need a lower dose if my kidneys are impaired?

Not according to the label. The prescribing information states that no dose adjustment is recommended for reduced kidney function, and studies in people with kidney impairment, including kidney failure, found no meaningful change in how the body handles semaglutide. The prescriber still sets the actual dose from your whole picture, not from kidney function alone.

What is eGFR, and why does my provider ask for it?

eGFR is an estimate of how fast your kidneys are filtering, calculated from a routine blood test. Around 90 or above is typical for a healthy adult, and readings that stay under 60 define chronic kidney disease. A provider wants a recent one before starting so there is a baseline to compare later results against, and so they can see how the rest of your medications fit around it.

Does the kidney finding apply to people without diabetes?

The August 2026 pooled analysis is the first strong evidence pointing that way. It combined FLOW with the SELECT and SOUL trials for 30,787 participants, and SELECT enrolled people with cardiovascular disease and obesity but no diabetes. Kidney events were less common on semaglutide across the whole pooled group, which is a much broader population than FLOW studied on its own.